Garsorasib
Garsorasib is a pharmaceutical drug used for cancer treatment. It is a selective inhibitor of the enzyme KRAS that has the G12C mutation.
In China, it is approved for the treatment of advanced non-small cell lung cancer carrying the KRAS G12C mutation in patients who have received at least one systemic treatment.